Vitro Biopharma, INC
Quarterly Earnings (10-Q)
Vitro BioPharma, Inc. filed its Form 10-Q for the quarter ended April 30, 2026, detailing a net loss of $1.55 million and highlighting substantial doubt about its ability to continue as a going concern.
Capital raise
Worse than expected
Vitro BioPharma reported a reduced net loss in Q1 2026 but continues to face substantial doubt about its ability to continue as a going concern due to significant working capital deficit and reliance on future capital raises.
Delay expected
Worse than expected
Capital raise
Vitro BioPharma reported a significant increase in its quarterly net loss and a worsening working capital deficit, raising substantial doubt about its ability to continue as a going concern.
Worse than expected
Capital raise
Delay expected
Vitro BioPharma, Inc. reported a significant reduction in net loss for the three and six months ended April 30, 2025, while acknowledging substantial doubt about its ability to continue as a going concern and actively pursuing new capital.
Delay expected
Worse than expected
Capital raise
Vitro Biopharma enters into a security agreement with holders of senior secured convertible notes, granting a lien on company assets to secure obligations under the purchase agreement and notes.
Capital raise
Annual Reports (10-K)
Vitro Biopharma, an innovative biotechnology company, reported increased net losses for fiscal year 2025, driven by debt extinguishment, while advancing its cell therapy pipeline for autoimmune and inflammatory disorders.
Delay expected
Capital raise
Worse than expected
10-K: Vitro Biopharma's 10-K Filing Reveals Focus on Cell Therapy Development Amidst Financial Challenges
Vitro Biopharma's 10-K filing highlights its ongoing development of AlloRx Stem Cell therapy for autoimmune and inflammatory diseases, while also addressing financial uncertainties and operational risks.
Capital raise
Worse than expected